Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company headquartered in Newport Beach, California. Established in 2012, Evolus is dedicated to providing innovative medical aesthetic products to physicians and their patients in the United States and Europe. The company's flagship product, Jeuveau, is a proprietary 900 kilodalton purified botulinum toxin type A formulation. It is specifically designed for the temporary improvement in the appearance of moderate to severe glabellar lines, commonly known as frown lines, in adults.
Evolus operates primarily in the self-pay aesthetic market, a unique segment where medical products are purchased by physicians and other customers and then sold to consumers or used in aesthetic procedures. This customer-centric approach positions Evolus to meet the growing demand for non-surgical cosmetic enhancements.
Recent Achievements:
- Successful expansion of Jeuveau sales across the United States and Europe.
- Strong partnerships with distribution partners in Canada, generating significant service revenue.
- Continued investment in research and development to enhance and expand their product offerings.
Current Projects:
- Exploring new formulations and applications for botulinum toxin type A to address other aesthetic and medical needs.
- Enhancing digital platforms to improve customer engagement and support for medical professionals.
With a firm commitment to providing high-quality aesthetic solutions, Evolus, Inc. is poised for future growth and innovation in the beauty industry.
News
Rhea-AI Summary
Evolus, Inc. (EOLS) reported positive financial results for Q4 2023 and full year 2023, with $0.8M cash generated from operating activities, a $3.7M non-GAAP operating loss for Q4, and $163.9M operating expenses. The company achieved a global net revenue record of $61.0M for Q4 and $202.1M for full year 2023, showing significant growth. Evolus updated its mid-term guidance, aiming for profitability in Q4 2024 and full year 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
-
Rhea-AI Summary
Evolus, Inc. (EOLS) announces statistical superiority of Evolysse™/Estyme® Lift dermal filler over Restylane-L in improving nasolabial fold severity. The European Lift study met the primary endpoint of non-inferiority. The filler line will be launched globally in 2025, branded as Evolysse™ in the US and Estyme® in the UK and Europe. The study demonstrated statistical superiority of Evolysse™/Estyme® Lift at 3 and 6 months, positioning it as a versatile and high-volume filler. Safety profiles were similar with no serious adverse events reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
-
Rhea-AI Summary
Evolus, Inc. (EOLS) announces participation in upcoming investor conferences in March 2024. Management team to present at Leerink Partners Global Biopharma Conference and Barclays Global Healthcare Conference. Webcast available on Evolus website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
Rhea-AI Summary
Evolus, Inc. (EOLS) announces the reporting of its fourth quarter and year-end 2023 financial results along with a business update on March 7, 2024. The company will host a conference call and live webcast to discuss the results, followed by a Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
-
Rhea-AI Summary
Evolus, Inc. grants 15,101 restricted stock units to 7 new non-executive employees under the 2023 Inducement Incentive Plan. The RSUs vest annually starting from February 7, 2024, subject to employment conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
-
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) reported preliminary unaudited net revenue of $61 million for Q4 2023, a 40% increase from the prior year quarter, and $202 million for full-year 2023, a 36% increase from 2022. The company exceeded its 2023 net revenue guidance and expects 2024 net revenue to grow by 26-31%. The company also achieved significant milestones, including the expansion of its portfolio with the addition of late-stage dermal fillers expected to be launched in the U.S. and Europe in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.65%
Tags
Rhea-AI Summary
Evolus, Inc. (EOLS) granted non-qualified stock options and restricted stock units to six newly hired non-executive employees under its 2023 Inducement Incentive Plan. The options have an exercise price of $10.68 per share, a 10-year term, and vest over 4 years, while the RSUs vest 25% on each annual anniversary of the vesting commencement date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
-
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) announced Nareg Sagherian as Vice President, Head of Global Investor Relations and Corporate Communications. Nareg brings extensive experience in capital markets, investor relations, corporate communications, and public policy from firms including FTI Consulting, Biotechnology Innovation Organization, and Booz Allen Hamilton. He will report to Sandra Beaver, Chief Financial Officer of Evolus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
-
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) has entered into a distributor agreement with Symatese to expand its dermal filler footprint beyond the U.S. to include the United Kingdom and Europe. European regulatory approvals are anticipated in the second half of 2024, with commercialization under the brand name Estyme® fillers in 2025. This agreement doubles the company's total addressable international market to $1.8 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) granted 28,328 restricted stock units (RSUs) to 7 non-executive employees under the 2023 Inducement Incentive Plan, with vesting over 4 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
FAQ
What is the current stock price of Evolus (EOLS)?
The current stock price of Evolus (EOLS) is $10.89 as of December 20, 2024.
What is the market cap of Evolus (EOLS)?
The market cap of Evolus (EOLS) is approximately 689.6M.
What is Evolus, Inc.?
Evolus, Inc. is a performance beauty company that provides medical aesthetic products to physicians and patients in the U.S. and Europe.
What is Jeuveau?
Jeuveau is a proprietary 900 kilodalton purified botulinum toxin type A formulation used to temporarily improve the appearance of moderate to severe frown lines in adults.
Where is Evolus headquartered?
Evolus is headquartered in Newport Beach, California.
When was Evolus founded?
Evolus was founded in 2012.
What market does Evolus primarily serve?
Evolus primarily serves the self-pay aesthetic market.
How does Evolus generate revenue?
Evolus generates product revenue from sales of Jeuveau in the U.S. and Europe, and service revenue from distribution partners in Canada.
What recent achievements has Evolus made?
Evolus has expanded Jeuveau sales in the U.S. and Europe and strengthened partnerships with Canadian distribution partners.
What are Evolus's current projects?
Evolus is working on new formulations and applications for botulinum toxin type A and enhancing digital platforms for better customer engagement.
Who are Evolus's primary customers?
Evolus's primary customers are physicians and other medical professionals who purchase their products for aesthetic procedures.
What is the significance of Jeuveau's formulation?
Jeuveau's formulation is significant because it offers a high-quality, non-surgical option for reducing frown lines, meeting the growing demand for aesthetic enhancements.
Evolus, Inc.
Nasdaq:EOLS
EOLS Rankings
EOLS Stock Data
689.57M
50.17M
12.31%
80.25%
8.35%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States of America
NEWPORT BEACH